An experimental vaccine targeting respiratory syncytial virus (RSV) was found to be nearly 82 percent effective for infants when administered to pregnant mothers, said data published by Pfizer on Wednesday.
Final data from the study was published in the  New England Journal of Medicine. The paper also said that the shot is 86 percent effective in preventing RSV infections in older adults.
A companion report published in the journal said the vaccine is 81.8 percent effective in protecting newborns from hospitalization associated with RSV. An expectant mother would have to receive the shot in her second or third trimester, according the paper.
In the trial, 3,682 maternal participants received vaccine and 3,676 received placebo and that 3,570 and 3,558 newborns, respectively, were evaluated….